36140348|t|GJA1/CX43 High Expression Levels in the Cervical Spinal Cord of ALS Patients Correlate to Microglia-Mediated Neuroinflammatory Profile.
36140348|a|Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting motoneurons (MNs) with a fatal outcome. The typical degeneration of cortico-spinal, spinal, and bulbar MNs, observed in post-mortem biopsies, is associated with the activation of neuroimmune cells. GJA1, a member of the connexins (Cxs) gene family, encodes for connexin 43 (Cx43), a core gap junctions (GJs)- and hemichannels (HCs)-forming protein, involved in cell death, proliferation, and differentiation. Recently, Cx43 expression was found to play a role in ALS pathogenesis. Here, we used microarray and RNA-seq datasets from the NCBI of the spinal cord of control (NDC) and ALS patients, which were stratified according to the GJA1 gene expression. Genes that positively or negatively correlated to GJA1 expression were used to perform a genomic deconvolution analysis (GDA) using neuroimmune signatures. Expression analysis revealed a significantly higher GJA1 expression in the MNs of ALS patients as compared to NDC. Gene deconvolution analysis revealed that positively correlated genes were associated with microglia activation, whereas negatively correlated genes were associated with neuronal activation profiles. Moreover, gene ontology analysis, performed on genes characterizing either microglia or neuronal signature, indicated immune activation or neurogenesis as main biological processes. Finally, using a synthetic analysis of drugs able to revert the GJA1 transcriptomic signatures, we found a specific drug profile for ALS patients with high GJA1 expression levels, composed of amlodipine, sertraline, and prednisolone. In conclusion, our exploratory study suggests GJA1 as a new neuro-immunological gene correlated to microglial cellular profile in the spinal cord of ALS patients. Further studies are warranted to confirm these results and to evaluate the therapeutic potential of drugs able to revert typical GJA1/CX43 signature in ALS patients.
36140348	0	4	GJA1	Gene	2697
36140348	5	9	CX43	Gene	2697
36140348	64	67	ALS	Disease	MESH:D000690
36140348	68	76	Patients	Species	9606
36140348	109	126	Neuroinflammatory	Disease	MESH:D000090862
36140348	136	165	Amyotrophic lateral sclerosis	Disease	MESH:D000690
36140348	167	170	ALS	Disease	MESH:D000690
36140348	189	215	neurodegenerative disorder	Disease	MESH:D019636
36140348	424	428	GJA1	Gene	2697
36140348	487	498	connexin 43	Gene	2697
36140348	500	504	Cx43	Gene	2697
36140348	645	649	Cx43	Gene	2697
36140348	689	692	ALS	Disease	MESH:D000690
36140348	798	801	NDC	Disease	
36140348	807	810	ALS	Disease	MESH:D000690
36140348	811	819	patients	Species	9606
36140348	860	864	GJA1	Gene	2697
36140348	932	936	GJA1	Gene	2697
36140348	1090	1094	GJA1	Gene	2697
36140348	1120	1123	ALS	Disease	MESH:D000690
36140348	1124	1132	patients	Species	9606
36140348	1148	1151	NDC	Disease	
36140348	1599	1603	GJA1	Gene	2697
36140348	1668	1671	ALS	Disease	MESH:D000690
36140348	1672	1680	patients	Species	9606
36140348	1691	1695	GJA1	Gene	2697
36140348	1727	1737	amlodipine	Chemical	MESH:D017311
36140348	1739	1749	sertraline	Chemical	MESH:D020280
36140348	1755	1767	prednisolone	Chemical	MESH:D011239
36140348	1815	1819	GJA1	Gene	2697
36140348	1918	1921	ALS	Disease	MESH:D000690
36140348	1922	1930	patients	Species	9606
36140348	2061	2065	GJA1	Gene	2697
36140348	2066	2070	CX43	Gene	2697
36140348	2084	2087	ALS	Disease	MESH:D000690
36140348	2088	2096	patients	Species	9606
36140348	Association	MESH:D011239	2697
36140348	Association	MESH:D020280	2697
36140348	Negative_Correlation	MESH:D017311	MESH:D000690
36140348	Association	MESH:D017311	2697
36140348	Association	MESH:D011239	MESH:D000690
36140348	Association	MESH:D000090862	2697
36140348	Positive_Correlation	MESH:D000690	2697
36140348	Association	MESH:D020280	MESH:D000690

